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Introduction: The purpose of this study was to evaluate the natural 
evolution of ground-glass nodules (GGNs) in the Multicentric Italian 
Lung Detection (MILD) trial, which adopted a nonsurgical approach 
to this subset of lesions.
Methods: From September 2005 to August 2007, 56 consecutive 
MILD participants with 76 GGNs were identified from 1866 indi-
viduals who underwent baseline low-dose computed tomography. 
The features of GGNs were assessed and compared with the corre-
sponding repeat low-dose computed tomographies after a mean time 
of 50.26 ± 7.3 months. The GGNs were classified as pure (pGGN) 
or part-solid (psGGN) GGNs. The average of the maximum and the 
minimum diameters for both pGGNs and psGGNs and the maximum 
diameter of the solid portion of psGGNs were manually measured. 
At follow-up, GGNs were classified as follows: resolved, decreased, 
stable, or progressed (according to three defined growth patterns).
Results: A total of 15 of 48 pGGNs (31.3%) resolved, 4 of 48 (8.3%) 
decreased in size, 21 of 48 (43.8%) remained stable, and 8 of 48 (16.7%) 
progressed. Among the psGGNs with a solid component smaller than 
5 mm, 3 of 26 (11.5%) resolved, 11 of 26 (42.3%) remained stable, 
and 12 of 26 (46.2%) progressed. One of the two psGGNs with a solid 
component larger than 5 mm remained stable, and the other decreased 
in size. Four lung cancers were detected among the GGN subjects, but 
only one arose from a psGGN, and was resected in stage Ia.
Conclusions: The progression rate of the GGNs toward clinically 
relevant disease was extremely low in the MILD trial and supports an 
active surveillance attitude.
Key Words: Ground-glass nodule, Lung cancer screening, Long-term 
surveillance.
(J Thorac Oncol. 2012;7: 1541-1546)
Subsolid lung nodules, also termed ground-glass nodules (GGNs), are often encountered during computed tomogra-
phy (CT) examinations for lung disease. They may represent a 
variety of disorders ranging from inflammatory abnormalities 
to lung neoplasms, and may indeed show different evolution 
over time.1–3 If it is true that some GGNs may be stable over 
time and more likely represent malignant or premalignant 
abnormality, a substantial proportion of them are instead tran-
sient.4–6 Indeed, despite the increased understanding during 
the last decade of the varieties of the GGNs, these lesions con-
tinue to represent a challenging task for clinicians, surgeons, 
and radiologists.
The difficulty in the management of the GGNs is 
particularly evident in the lung cancer screening setting, 
partly because of the scarce information on these enti-
ties at the time in which multicentric randomized trials 
were designed.7,8 Furthermore, there are important data 
consistent with the notion of overdiagnosis occurring in a 
considerable percentage of screening-detected lesions.9–11 
However, the nonuniform management strategies for these 
lesions across the lung cancer screening trials may give the 
possibility of achieving additional important information in 
this regard.
Thus, the purpose of this study was to evaluate the evo-
lution of the GGNs in the Multicentric Italian Lung Detection 
(MILD) trial, which adopted a very conservative, nonsurgical 
approach to this subset of lesions.
PATIENTS AND METHODS
Study Population
The study population comprised all the consecu-
tive patients who underwent baseline low-dose (LD) CT 
(LDCT) examination between September 2005 and August 
2007 (n = 1866, 1280 men, 68.6%, and 586 women, 31.4%; 
mean age 57.6 ± 4.8 years) as part of the MILD project at 
the National Cancer Institute of Milan. The MILD project 
is an ongoing multicentric population-based randomized, 
controlled, lung cancer screening trial, and its primary aim 
is the impact of early lung cancer detection on mortality. 
The MILD project was approved by the Institutional Review 
Boards, and written informed consent was obtained from 
all participants. For this substudy, the original Institutional 
Review Boards’ approval and informed consent allowed use 
of data for future research.
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Part of the study subjects had been included in other 
studies addressing a separate hypothesis.12,13 Eligibility crite-
ria for the MILD included: 49 to 75 years of age, current or 
former smokers (having quit smoking within 10 years before 
recruitment) with at least 20 pack-years of smoking history 
and no history of cancer within the previous 5 years. Details of 
MILD eligibility criteria, randomization protocol, lung nod-
ule detection, and management protocol have been previously 
described.12
LDCT Technique
LDCT was performed by using a 16-detector row 
CT scanner (Somatom Sensation 16, Siemens Medical 
Solutions, Forchheim, Germany). All LDCT scans of 
the whole lung were acquired during one deep inspira-
tory breath-hold without the use of the contrast medium. 
Standard LDCT parameters were as follows: 120 kV, effec-
tive 30 mAs, individual detector collimation 0.75 mm, gan-
try rotation time 0.5 second, pitch 1.5. LDCT images for 
the lung nodule detection were reconstructed as follows: 
1-mm–thick sections with a reconstruction increment of 
1 mm (medium-sharp kernel - B50f).
Original MILD Management of the GGNs
Using defined criteria, radiologists working for the 
MILD trial (MILD readers) were asked to report the pres-
ence of any pure (pGGN) and part-solid (psGGN) GGNs. 
According to the MILD protocol, both pGGNs and psGGNs 
with a solid component smaller than 5 mm had to be followed 
up regardless of their size and their number (i.e., single or mul-
tiple). These subjects were scheduled for repeat LDCT scan-
ning according to both their LDCT arm of randomization and 
other lung findings.12 Only the psGGNs with a solid compo-
nent larger than 5 mm were considered suspicious for malig-
nancy and indeed followed up at 1 year (if sized 5 to 8 mm) 
or evaluated by positron emission tomography (PET) scanning 
and invasive diagnostic procedures (if sized more than 8 mm) 
as jointly established by the senior MILD radiologist (AM) and 
the thoracic surgeon (UP) coordinating the MILD trial.
Radiologic Assessment of the 
GGNs by Core Readers
For the present study, all the LDCTs were reviewed 
on three different personal computers running a Dicom 
viewer software validated for clinical purpose (OsiriX, 3.5.1 
Imaging Processing Software, 64-bit format, Pixmeo SARL, 
Bernex, Switzerland) by three readers (core readers) as fol-
lows: MS, CM, and GN reviewed 1203, 483, and 200 LDCT 
scans, respectively. The core readers were in the course of 
their training as thoracic radiology subspecialists at the 
Academic Hospital of Parma and they had 2 years’ experi-
ence in interpreting thin-section CT scans. The core read-
ers were blinded to the original interpretations by the MILD 
readers. They received specific training, which consisted of 
viewing a slide presentation that defined and showed exam-
ples of lesions having various features and understanding the 
current literature.
In cases of uncertain diagnosis, the core readers were 
instructed to classify the corresponding LDCT findings as 
positive, because these would have to be reviewed with a 
chest radiologist (NS with 5 years of experience in interpret-
ing LDCTs lung cancer screening) who would then decide 
to maintain or discard the evaluations of the core readers. 
Subsequently, the core readers and the chest radiologist jointly 
classified each selected GGN as pGGN or psGGN.
Both baseline and the latest corresponding follow-up 
LDCT were evaluated for the GGNs measurements only by 
one of the three core readers (MS). For the pGGNs, both the 
maximum length and the width (defined as the longest diam-
eter perpendicular to length on the same CT image) were 
measured. The GGN size was defined as the average of these 
two measurements.14 For the psGGNs, the maximum length of 
the solid component was also measured. Measurements were 
manually determined using the electronic caliper. All these 
measurements were also repeated after 4 months by another 
core reader (CM) to evaluate the interobserver variability. 
Then, the core readers, the chest radiologist, and one thoracic 
surgeon coordinating the MILD trial reviewed in consensus 
both the baseline and the latest follow-up LDCT images to 
evaluate any change in attenuation (e.g., development of any 
solid component within a pure GGN) of the GGNs.
Data Analysis
At follow-up LDCT, each pGGN was classified as 
follows: resolved, decreased (by at least 2 mm as compared 
with the same nodule at baseline LDCT), stable, or increased 
(by at least 2 mm as compared with the same nodule at base-
line LDCT). The development of a solid component within 
a pGGN was also considered a sign of progression/malig-
nancy. Similar criteria were applied to psGGNs as follows: 
decreased (if the solid component alone or along with the 
total average size by at least 2 mm as compared with the 
same nodule at baseline LDCT), stable (including no varia-
tion of the solid component associated with a decrease of 
the total average size), and increased. The increase of the 
GGNs was subclassified into three growth patterns: (1) an 
increase by at least 2 mm of the solid component (Fig. 1A); 
(2) an increase by at least 2 mm of the total average size 
(Fig. 1B); and (3) an increase of both the solid component 
and total average size of at least 2 mm (Fig. 1C). The 2-mm 
threshold was based on intraobserver variation data reported 
by a prior study.15
Evolution of the GGNs was stratified either by the 
MILD original classification system (i.e., pGGNs, psGGNs 
with a solid component < 5 mm, and psGGNs with a solid 
component > 5 mm) or by the interim guidelines proposed 
by Godoy et al.8 as follows: solitary pGGNs with the 
maximum diameter smaller than 5 mm, solitary pGGNs 
between 5 and 9 mm, solitary pGGNs larger than 10 mm, 
solitary psGGNs of any size, and multiple GGNs. To 
determine variability, we calculated the 95% confidence 
interval (CI) for the limits of agreement by using Bland-
Altman analysis.16 Normally distributed data are shown as 
means ± SD. p Values of less than 0.05 were considered to 
indicate statistical significance.
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RESULTS
At baseline, the core readers identified 76 GGNs in 56 of 1866 
MILD participants (3%) (30 men, 53.6%, and 26 women, 
46.4%; mean age 59.7 ± 5.2 years). The MILD readers had 
originally identified 11 of 1866 subjects (0.6%) with 13 
GGNs, which were then all detected by the core readers.
At baseline, the mean size of the GGNs was 6.97 ± 2 mm. 
Forty-four participants (78.6%) had a solitary GGN, whereas 
12 participants (21.4%) had multiple GGNs as follows: two 
in eight subjects (14.3%), three in two (3.6%) subjects, and 
five in two subjects (3.6%). A total of 48 of 76 (63.2%) 
were pGGNs (6.7 ± 1.9 mm), whereas 28 of 76 (36.8%) were 
psGGNs (7.5 ± 1.9 mm). Only two of 28 psGGNs (7.1%) 
displayed a solid component larger than 5 mm, of 7 mm and 
12 mm, respectively. Both these lesions were identified either 
by the core or the MILD readers.
For the manually measured GGN size, the 95% CI for 
the limits of agreement was −1.9, 2.2 mm for interobserver 
variability at baseline and −2.1, 2.2 mm for interobserver 
variability at follow-up. For the solid component diameter, 
FIGURE 1. A, Growth pattern 1: 
increase of the sole solid component. 
Any increase or decrease in size is 
defined as a variation of at least 
2 mm. B, Growth pattern 2: increase 
of the total average size.Any increase 
or decrease in size is defined as a 
variation of at least 2 mm. C, Growth 
pattern 3: increase of both the solid 
component and total average size. 
Any increase or decrease in size is 
defined as a variation of at least 
2 mm. * indicates solid component; 
§, average size.
TABLE 1. Evolution of the Ground-Glass Nodules According to the Mild Protocol
pGGNs
psGGNs
With a Solid Component < 5 mm With a Solid Component > 5 mm
Baseline 48
(6.7 ± 1.9 mm)
26
(7.4 ± 1.9 mm)
2
(8.5 ± 2 mm)
Resolved at follow-up 15 3 0
Decreased in size at follow-up 4
(−4.25 ± 0.75 mm)
0 1
(0.5 mm)a
(−12 mm)b
Stable at follow-up 21
(0.07 ± 0.71 mm)
11
(0.17 ± 1.86 mm)a
(0.09 ± 0.83 mm)b
1(0.5 mm)a
(0 mm)b
Grown at follow-up
Pattern 1 0 3
(0.5 ± 0.33 mm)a
(4.67 ± 1.78 mm)b
0
Pattern 2 7(4.42 ± 0.61 mm) 5c
(3.4 ± 0.32 mm)a
(0.4 ± 0.48 mm)
b
0
Pattern 3 1d
(6.5 mm)b
4(3 ± 1 mm)a
(3.75 ± 1.75 mm)b
0
aAverage size.
bSolid component.
cOne lung cancer arose from one psGGN showing a growth pattern 2.
dNewly developed solid component.
pGGN, pure ground-glass nodules; psGGN, part-solid ground-glass nodules.
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the 95% CI for the limits of agreement was −1.6, 1.5 mm 
for interobserver variability at baseline and −2, 1.9 mm for 
interobserver variability at follow-up.
The majority (47 of 76, 61.8%) of the GGNs were iden-
tified in the upper lobes. Specifically, the GGN distribution 
was as follows: 25 GGNs (32.9%) in the right upper lobe, 24 
GGNs (31.6%) in the left upper lobe, 13 GGNs (17.1%) in the 
right lower lobe, nine GGNs (11.8%) in the left lower lobe, 
and five GGNs (6.6%) in the middle lobe.
The evolution of the GGNs after a mean follow-up of 
50.26 ± 7.3 months is summarized in Table 1. A total of 15 
of 48 pGGNs (31.3%) completely resolved (mean follow-
up of 44.68 ± 10.53 months), four of 48 pGGNs (8.3%) 
decreased in size (−4.25 ± 0.75 mm after a mean follow-up 
of 52.67 ± 6.18 months), 21 of 48 pGGNs (43.8%) remained 
stable (mean follow-up time of 53.02 ± 6.78 months), and 
eight of 48 pGGNs (16.7%) increased in size (4.1 ± 1.8 mm, 
50 ± 0.2% after a mean follow-up of 55.53 ± 6.47 months). 
Only one pGGN developed a solid component of 5 mm after 
63.9 months; this patient, however, arbitrarily abandoned the 
screening program after the last follow-up LDCT examina-
tion. Three patients with pGGNs also underwent PET-CT 
scanning because of the presence of one solid lesion located 
in the same lobe of the pGGN. Two of these solid nodules 
were positive at PET-CT scanning; of these, one resulted in 
a stage Ia adenocarcinoma and the other resulted in a pleural 
adenocarcinoma after surgery.
A total of three of 26 psGGNs (11.5%) completely 
resolved in two subjects (mean follow-up of 54.54 ± 2.73 
months), whereas 11 of 26 psGGNs (42.3%) were stable 
(mean follow-up of 53.7 ± 5.4 months). One baseline psGGNs 
with a solid component of 12 mm was negative at PET-CT 
scanning and lost its solid component after 54 months, 
thus transforming into a pGGN. The other lesion with a 
solid component of 7 mm at baseline was only followed up 
and remained stable after 51 months. The majority of the 
remaining psGGNs (i.e., with a solid component < 5 mm 
at baseline) progressed in nine subjects (mean follow-up 
of 52.11 ± 3.9 days). Specifically, a growth pattern 1 (mean 
increase of the solid component 4.67 ± 1.78 mm) was recorded 
in three of 26 psGGNs (11.5%), a growth pattern 2 (mean 
increase of the average size 3.4 ± 0.32 mm) was recorded in 
five of 26 psGGNs (19.2%), whereas a growth pattern 3 (mean 
increase of the average size 3 ± 1 mm; mean increase of the 
solid component 3.75 ± 1.75 mm) was observed in four of 26 
psGGNs (15.4%).
A total of eight subjects with at least one psGGN under-
went PET-CT scanning. Specifically, two of eight subjects 
(25%) underwent PET-CT scanning because of a coexisting 
solid nodule in a different lobe of the stable psGGN (aver-
age size 4.75 ± 0.25 mm; solid component 2.5 ± 0.5 mm). In 
these cases, both psGGNs and solid nodules were negative on 
PET-CT. The remaining six of eight cases (75%) had a growing 
psGGN: one psGGN (average size 11 mm; solid component 
10 mm) positive on PET-CT turned out to be a stage Ia pul-
monary adenocarcinoma after surgery; one psGGN (average 
size 12.5 mm; solid component 10 mm) negative on PET-CT 
was associated with a positive concomitant solid nodule in a 
TABLE 2. Evolution of the Ground-Glass Nodules According to the Interim Guidelines
Solitary GGNs Multiple GGNs
pGGNs 
<5 mm
pGGNs 
5–9 mm
pGGNs 
>10 mm psGGNs
pGGNs 
<10 mm
pGGNs 
≥10 mm psGGNs
Baseline 0
26
(6.3 ± 1.0 mm)a
4
(14.5 ± 3.5 mm)a
14
(8.7 ± 2.9 mm)a
(3.6 ± 1.9 mm)b
13
(6.2 ± 1.4 mm)a
5
(12.0 ± 1.6 mm)a
14
(8.1 ± 2.0 mm)a
(2.4 ± 1.1 mm)b
Resolved at  
follow-up 0 6 2 0 6 1 3
Decreased in  
size at follow-up 0 0
1
(−8 mm)a
1
(0 mm)a
(−12 mm)b
2
(−4.5 ± 1.5 mm)a
2
(−3.0 ± 1.0 mm)a
1
(0.0 mm)a
(−2.0 mm)b
Stableat follow-up 0
17
(−0.1 ± 0.6 mm)a 0
7
(−0.86 ± 2.12 mm)a
(0.43 ± 0.53 mm)b
2
(0.0 ± 0.0 mm)a 0
1
(1.0 mm)a
(0.0 mm)b
Grown at follow-up
Pattern 1 0 0 0
3
(0.7 ± 0.4 mm)a
(3.3 ± 1.8 mm)b 0 0
1
(−1.0 mm)a
(6.0 mm)b
Pattern 2 0
3
(3.7 ± 0.9 mm)a 1(3 mm)a
3
(2.7 ± 0.4 mm)a
(0.0 ± 0.0 mm)b
2
(5 ± 3 mm)a
2
(5.0 ± 1.0 mm)a
5c
(4.0 ± 0.8 mm)a
(0.4 ± 0.5 mm)b
Pattern 3 0 0 0 0
1
(6 mm)a
(5 mm)b 0
3
(5.3 ± 2.2 mm)a
(4.3 ± 01.8 mm)b
aAverage size.
bSolid component.
cOne lung cancer arose from one psGGN showing a growth pattern 2.
dNewly developed solid component.GGNs, ground-glass nodules ; pGGN, pure ground-glass nodules; psGGN, part-solid ground-glass nodules.
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different lobe, which resulted a stage IV pulmonary neuro-
endocrine tumor after surgery; the remaining four growing 
psGGNs (average size 11.75 ± 2.95 mm; solid component 
8.75 ± 1.49 mm) were negative on PET-CT. One subject with 
a growth pattern 2 psGGN did not undergo PET-CT scanning 
and is still under evaluation.
According to the interim guidelines, a total of five of 
18 multiple pGGNs (27.8%) and four of 30 solitary pGGNs 
(13.3%) increased in size at follow-up. The proportion of 
increasing psGGNs was similar between solitary and multiple 
lesions (Table 2).
DISCUSSION
This study shows a variable evolution for the GGNs at 
long-term follow-up. Our findings increase the current con-
cerns about the optimal balance between the need for a prompt 
surgical intervention for invasive lung cancer and the need to 
limiting overtreatment for indolent disease.
First, we found that the most GGNs were originally 
overlooked by the MILD readers. The discrepant detection 
rate between the MILD and the core readers is in keeping 
with prior studies reporting a sizeable nodule miss rate in 
the screening setting.17,18 The main concern of identifying all 
noncalcified solid nodules and the scarce understanding of 
GGNs at the time in which the study cases were originally 
interpreted by the MILD readers might have increased the 
subsolid nodule miss rate. Second, the MILD criteria—only 
psGGNs with a solid component larger than 5 mm or pGGNs 
developing a solid component over time were considered sus-
picious for malignancy—might have led the MILD readers to 
be less careful in reporting other GGNs. Nevertheless, all the 
psGGNs with a solid component larger than 5 mm were identi-
fied by the MILD readers.
According to the MILD protocol, both pGGNs and 
psGGNs with a barely measurable solid component were 
regarded unworthy of any immediate surgical intervention. 
They were considered as pre- or low-grade neoplastic forms 
that might represent overdiagnosis of lung cancer—that is, 
that it progresses so slowly as to be inconsequential—or rep-
resent inflammatory changes in their vast majority. Despite its 
questionability, such a conservative management has allowed 
the evaluation of the natural course of these lesions. To our 
knowledge, no other lung cancer screening trial has described 
the evolution for the whole spectrum of the GGNs for such a 
long-term follow-up.
We observed that combined resolving, decreasing in 
size and stable nodules (54 of 76, 71.1%) constituted the 
majority of the GGNs. In our study, the frequency of transient 
GGNs (23.7%) was lower than that reported by previous stud-
ies (37–70%) despite the longer follow-up.5,6,19 Transiency was 
more frequently observed among pGGNs as compared with 
psGGNs, whereas a large solid portion was an independent 
predictor of transiency in a prior investigation.6 Of note, the 
few resolving psGGNs were observed only when they were 
multiple. Such a difference with prior investigations might be 
explained by several factors such as the different participants’ 
eligibility criteria. For example, the study population evalu-
ated by Lee et al.6 was more heterogeneous for both smoking 
history (as never smokers were also included) and age range 
(26–79 years) as compared with the study population of 
MILD. Besides, we have evaluated only the GGNs detected 
at baseline, whereas those detected at follow-up proved more 
likely to be transient in the study by Lee et al.6 Our findings 
are in keeping with those of other studies that showed that the 
larger the solid component, the greater the likelihood it was 
proved to be not transient.20
We found that the majority of the pGGNs remained sta-
ble over time. Although the stratification of the pGGNs accord-
ing to their size may be useful to decide the best approach to 
each subset of lesions, our data cannot provide any evidence 
in this regard because of the small number of cases whose size 
was smaller than 5 mm and larger than 10 mm. However, even 
some pGGNs increased in size, particularly when they were 
multiple. In addition, two cases developed a solid tumor in the 
same lobe of the pGGN. A bit surprisingly, we found that only 
one pGGN developed (after 63.9 months) a newly solid com-
ponent that, however, could not be further investigated as that 
participant arbitrarily abandoned the screening. Therefore, our 
findings are in keeping with previous observations suggesting 
that traditional follow-up periods of 2 or 3 years may be insuf-
ficient to safely diagnose benign disease for the pGGNs.8,21
We found that decreased-in-size nodules represented the 
minority of cases. However, it should be taken into account 
that some tumors may show an irregular growth pattern, 
which includes a decrease in size at some time point.20 In our 
view, a longer follow-up period is needed to understand the 
nature of these GGNs because lung surgery is not warranted 
for decreased in size lesions.
The finding that nearly half (46.2%) of the psGGNs 
increased in size is consistent with the greater likelihood of 
malignancy or premalignancy for this subset of lesions. In a 
study by Li et al. 21 69% of lung cancers missed by radiolo-
gists at screening CT were found to be psGGNs. A substantial 
delay in biopsy was also reported by the New York Early Lung 
Cancer Action Project study for 10 cancers that manifested 
as psGGNs or pGGNs at baseline.7 In one case in the pres-
ent study cohort, an immediate resection of a solitary psGGN 
would have probably hampered the surgical treatment of a 
large solid tumor that occured later in the contralateral lung.
The MILD strategy entailing the selective use of 
PET-CT for the evaluation of the psGGNs may be question-
able because of the PET high false-negative rate for identify-
ing neoplastic GGNs.22–24 However, in more than 10 years of 
systematic use of PET in lung cancer screening, we have not 
experienced any relevant diagnostic problem. In fact, false-
negative PET invariably represents slow-growing disease 
that can be monitored for growth assessment and eventually 
resected in early stage. Conversely, the quantification of PET 
standard uptake value might provide useful information on 
the biologic features of CT-detected lesions, and also disclose 
which multiple lesions should be resected.8
All measurements were obtained manually and were 
indeed subject to interobserver variability. In a post hoc analy-
sis, we found that the levels of interobserver variability for 
measurements of the solid component and the global size of 
the GGNs were similar to those reported by De Hoop et al.15 
As proposed by the same authors, the use of a change in lesion 
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mass proved to be more accurate than simple measurements of 
lesion diameter by the electronic caliper, resulting in markedly 
improved inter- and intraobserver agreement and a substan-
tial decrease in the time necessary to detect interval growth.15 
Future studies assessing GGNs mass changes over time are 
needed to further explore this topic.
This study has several limitations. A number of the pul-
monary nodules detected in our study are currently being fol-
lowed up, and the verified diagnostic outcome (pathology or 
otherwise) for most subjects is unavailable. Nevertheless, the 
observation that no GGN progressed into a clinical disease or 
increased in size so rapidly to hamper any curative lung resec-
tion provides further information on the natural evolution of 
these subtypes of lesions. In line with our findings, Sawada et 
al.22 suggested that long follow-up period for lung cancer pre-
senting as GGN did not cause any important treatment delay 
and did not negatively influence the final outcome.
By classifying the GGNs according to the interim 
guidelines we found that 29 of 56 subjects (51.8%) should 
have undergone surgical resection. Such a high propor-
tion adds further questions on the optimal management of 
GGNs in the screening programs, facing two major issues: 
unnecessary treatment of indolent tumors or benign abnor-
malities because of overdiagnosis on the one hand, and the 
need of resecting potentially aggressive lung tumors earlier 
on the other hand. Although we cannot draw any conclu-
sions on the optimal management of the GGNs, the conser-
vative MILD approach to GGNs was also rewarded by the 
lower proportion of invasive procedures that revealed benign 
disease as compared with other screening results (9% ver-
sus 27.2%).23 Furthermore, we did not specifically address 
the issue of the GGNs features that best predict their evolu-
tion as this was beyond the scope of the present study and 
it was already explored by previous investigations.27, 28 It is 
also worth emphasizing that our data were observed across a 
study cohort of current or former smokers recruited by a lung 
cancer screening trial and evaluated by a specific CT pro-
tocol. Therefore the conservative management of the GGNs 
suggested by our study might not apply to patients evaluated 
in routine practice. Further studies are needed to evaluate the 
evolution of the GGNs out of the screening context and to 
standardize the CT technique for it.
In conclusion, by providing a large snapshot of the 
natural evolution of different GGNs, our study indicates the 
lack of clinical disease progression of these entities, and 
supports an active surveillance attitude.
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